Add to Watchlist
View Current for PTGX
View SuperFeed for PTGX
View Charts for PTGX
Add or remove $PTGX from your watchlists:
Hang tight! We're updating your watchlist data.
This might take a minute...
Protagonist Therapeutics Inc
Health Care
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and im… more
Thread Explorer
Explore popular threads around $PTGX
There are no threads for this stock
Go to Thread Explorer
Chart Explorer
Explore recent charts, graphs, and media
There are no charts for this stock
Latest News
Get the latest breaking news from the community
There is no recent news for this stock
Loading news, hang tight...
Google Search Trends - Past 12 months
Instantly visualize search trends for this specific symbol
Company Profile
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Market Cap Type: Small